Charles River Laboratories International logo

CRL

Charles River Laboratories International

$226.2

Earnings Summary

Revenue
$585.3Mn
Net Profits
$60.4Mn
Net Profit Margins
10.32%

Highlights

Revenue:

Charles River Laboratories International’s revenue jumped 26.08% since last year same period to $585.3Mn in the Q3 2018. On a quarterly growth basis, Charles River Laboratories International has generated -0% fall in its revenue since last 3-months.

Net Profits:

Charles River Laboratories International’s net profit jumped 15.1% since last year same period to $60.4Mn in the Q3 2018. On a quarterly growth basis, Charles River Laboratories International has generated 12.46% jump in its net profits since last 3-months.

Net Profit Margins:

Charles River Laboratories International’s net profit margin fell -8.7% since last year same period to 10.32% in the Q3 2018. On a quarterly growth basis, Charles River Laboratories International has generated 12.46% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Charles River Laboratories International post its latest quarter earnings

EPS Estimate Current Quarter
2.77
EPS Estimate Current Year
2.77

Highlights

EPS Estimate Current Quarter:

Charles River Laboratories International’s earning per share (EPS) estimates for the current quarter stand at 2.77 - a 9.06% jump from last quarter’s estimates.

EPS Estimate Current Year:

Charles River Laboratories International’s earning per share (EPS) estimates for the current year stand at 2.77.

Key Ratios

Key ratios of the Charles River Laboratories International post its Q2 2022 earnings

Earning Per Share (EPS)
2.77
Return on Assets (ROA)
0.06
Return on Equity (ROE)
17.27

Highlights

Earning Per Share (EPS):

Charles River Laboratories International’s earning per share (EPS) jumped 6.13% since last year same period to 2.77 in the Q2 2022. This indicates that the Charles River Laboratories International has generated 6.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Charles River Laboratories International’s return on assets (ROA) stands at 0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Charles River Laboratories International’s return on equity (ROE) stands at 17.27.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
2.72
2.75
1.1%
2022-08-03
2.74
2.77
1.09%

Company Information

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Organisation
Charles River Laboratories International
Headquarters
251 Ballardvale Street, Wilmington, MA, United States, 01887
Employees
18600
Industry
Commercial Services
CEO
James Foster

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*